DiscoverCME in Minutes: Education in Primary CareChristoph U. Correll, MD - Transforming the Treatment of Schizophrenia: Moving Beyond Anti-Dopaminergic Antipsychotics to Muscarinic Receptor Agonists
Christoph U. Correll, MD - Transforming the Treatment of Schizophrenia: Moving Beyond Anti-Dopaminergic Antipsychotics to Muscarinic Receptor Agonists

Christoph U. Correll, MD - Transforming the Treatment of Schizophrenia: Moving Beyond Anti-Dopaminergic Antipsychotics to Muscarinic Receptor Agonists

Update: 2024-11-06
Share

Description

Please visit answersincme.com/DKN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses antipsychotics in schizophrenia. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting muscarinic receptors in the treatment of schizophrenia; Describe the clinical implications of evidence on muscarinic receptor agonists in the treatment of schizophrenia; and Outline strategies for optimally incorporating muscarinic receptor agonists into the treatment of patients with schizophrenia.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Christoph U. Correll, MD - Transforming the Treatment of Schizophrenia: Moving Beyond Anti-Dopaminergic Antipsychotics to Muscarinic Receptor Agonists

Christoph U. Correll, MD - Transforming the Treatment of Schizophrenia: Moving Beyond Anti-Dopaminergic Antipsychotics to Muscarinic Receptor Agonists

Answers in CME